Last ¥359.00 JPY
Change Today -14.00 / -3.75%
Volume 404.8K
4563 On Other Exchanges
As of 2:00 AM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

anges mg inc (4563) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/5/13 - ¥1,144
52 Week Low
05/21/14 - ¥279.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ANGES MG INC (4563)

Related News

No related news articles were found.

anges mg inc (4563) Related Businessweek News

No Related Businessweek News Found

anges mg inc (4563) Details

AnGes MG, Inc., a biopharmaceutical company, is engaged in the research and development, and practical application of genetic medicines. The company is primarily developing Hepatocy growth factor (HGF) genetic medicine, which improves blood circulation by regenerating blood vessels. Its products pipeline includes Collategene for the treatment of peripheral arterial diseases, ischemic heart diseases, Parkinson’s disease, and lymphedema; NFkB decoy oligonucleotide for the treatment of atopic dermatitis and disc degeneration; NFkB decoy oligonucleotide coated PTA balloon catheter for the prevention of vascular restenosis; and CUREPEPTIN functional peptides for the treatment of wounds. The company also provides Naglazyme for the treatment of mucopolysaccharidosis; and CIN therapeutic vaccine for cervical cancer. It has strategic alliances with Daiichi Sankyo Company, Limited for the development of HGF genetic medicine in the fields of peripheral arterial disease and Ischemic heart disease; with Vical, Inc. for the development of Allovectin; and with BioLeaders Corporation for the development of therapeutic vaccine for cervical intraepithelial neoplasia. The company was formerly known as MedGene Bioscience Co., Ltd. and changed its name to AnGes MG, Inc. in October 2001. AnGes MG, Inc. was founded in 1999 and is headquartered in Ibaraki, Japan.

38 Employees
Last Reported Date: 03/31/14
Founded in 1999

anges mg inc (4563) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anges mg inc (4563) Key Developments

AnGes MG, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014; Provides Earnings Guidance for the Full Year Ending December 31, 2014

AnGes MG, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2014. For the quarter, the company reported revenues of JPY 82 million against JPY 125 million against a year ago. Operating loss was JPY 476 million against JPY 328 million against a year ago. Loss before income taxes and minority interests was JPY 436,608,000 against JPY 364,446,000 a year ago. Ordinary loss was JPY 436 million against JPY 337 million against a year ago. Net loss was JPY 438 million against JPY 366 million a year ago. Net loss per share was JPY 14.04 against JPY 13.27 a year ago. The company provided earnings guidance for the full year ending December 31, 2014. For the year, the company expects revenues to be from JPY 750 million to JPY 850 million. Operating loss is expected to be from JPY 2,600 million to JPY 2,400 million. Ordinary loss is expected to be from JPY 2,600 million to JPY 2,400 million. Net loss is expected to be JPY 2,600 million to JPY 2,400 million. Net loss per share is expected form JPY 83.15 to JPY 76.76.

AnGes MG, Inc. to Report Q1, 2014 Final Results on May 09, 2014

AnGes MG, Inc. announced that they will report Q1, 2014 final results on May 09, 2014

AnGes MG, Inc., Q4 2013 Earnings Call, Feb 10, 2014

AnGes MG, Inc., Q4 2013 Earnings Call, Feb 10, 2014


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4563:JP ¥359.00 JPY -14.00

4563 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4563.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4563 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGES MG INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at